[go: up one dir, main page]

MX2009003882A - Compuestos heteroaromaticos biciclicos. - Google Patents

Compuestos heteroaromaticos biciclicos.

Info

Publication number
MX2009003882A
MX2009003882A MX2009003882A MX2009003882A MX2009003882A MX 2009003882 A MX2009003882 A MX 2009003882A MX 2009003882 A MX2009003882 A MX 2009003882A MX 2009003882 A MX2009003882 A MX 2009003882A MX 2009003882 A MX2009003882 A MX 2009003882A
Authority
MX
Mexico
Prior art keywords
alkyl
alkoxy
aryl
halo
group
Prior art date
Application number
MX2009003882A
Other languages
English (en)
Inventor
Colin Andrew Leach
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2009003882A publication Critical patent/MX2009003882A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (I) (ver fórmula (I)) en donde: R1 es un grupo arilo, sustituido o no sustituido por 1, 2, 3 o 4 sustituyentes que pueden ser iguales o diferentes seleccionados del grupo que consiste de alquilo de C1-C6, alcoxi de C1-C6, alquiltio de C1-C6 arilalcoxi de C1-C6, hidroxi, halógeno, CN, COR6, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, halógeno alquilo de C1-C4, y halógeno alcoxi de C1-C4; W es CH y X es N, o W es N y X es CH, o W y X son CH; Y es alquilo de C2-C4, R2 es hidrógeno, alquilo de C1-C6, alcoxi de C1-C6, alquilito de C1-C6, arilalcoxi de C1-C6, hidroxi, halógeno, CN, COR6, carboxi COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, mono a perfluoro-alquilo de C1-C6, o mono a perfluoro-alcoxi de C1-C6; n es 0-5; R3 es alquilo de C1-C4; R4 es alquilo de C1-C4; R5 es hidrógeno, alquilo de C1-C10, alquenilo de C2-C10, alquinilo de C2-C10, halógeno alquilo de C1-C4, cicloalquilo de C3-C8, cicloalquilo de C3-C8, cicloalquilo de C3-C8 alquilo de C1-C4, cicloalquenilo de C5-C8, cicloalquenilo de C5-C8 alquilo de C1-C4, heterocicloalquiolo de C3-C8-miembros, heterocicloalquilo de 3-8 miembros alquilo de C1-C4, arilo de C6-C14, arilo de C6-C14 alquilo de C1-C10, heteroarilo, o heteroarilalquilo de C1-C10; en donde cada grupo es opcionalmente uno o más veces el mismo y/o diferente de un grupo que es alcoxi de C1-C6, alquiltio de C1-C6 arilalcoxi de C1-C6, hidroxi, halógeno, CN, NR8R9, o halógeno alcoxi de C1-C4; R6 y R7 son independientemente hidrógeno o alquilo de C1-C10; R8 y R9 son iguales o diferentes y son hidrógeno o alquilo de C1-C10, o R9 y R10 conjuntamente con el nitrógeno al cual están unidos forman un anillo de 5-7 miembros que contienen opcionalmente uno o más heteroátomos adicionales seleccionados de oxigeno, nitrógeno y azufre, y opcionalmente sustituidos por uno o dos sustituyentes seleccionados del grupo que consiste de hidroxi, oxo, alquilo de C1-C4, alquilcarboxi de C1-C4, arilo, y arilalquilo de C1-C4; o una sal farmacéuticamente aceptable del mismo; estos compuestos son útiles para el tratamiento de ateroesclerosis u otras enfermedades inflamatorias.
MX2009003882A 2006-10-13 2007-10-12 Compuestos heteroaromaticos biciclicos. MX2009003882A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82932806P 2006-10-13 2006-10-13
US11/626,882 US7705005B2 (en) 2006-10-13 2007-01-25 Bicyclic heteroaromatic compounds
PCT/US2007/081165 WO2008048866A2 (en) 2006-10-13 2007-10-12 Bicyclic heteroaromatic compounds

Publications (1)

Publication Number Publication Date
MX2009003882A true MX2009003882A (es) 2009-04-22

Family

ID=39303784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003882A MX2009003882A (es) 2006-10-13 2007-10-12 Compuestos heteroaromaticos biciclicos.

Country Status (15)

Country Link
US (1) US7705005B2 (es)
EP (1) EP2081915A4 (es)
JP (1) JP2010506851A (es)
KR (1) KR20090079227A (es)
AU (1) AU2007312995A1 (es)
BR (1) BRPI0719861A2 (es)
CA (1) CA2672926A1 (es)
CO (1) CO6180449A2 (es)
CR (1) CR10729A (es)
EA (1) EA200970379A1 (es)
IL (1) IL197960A0 (es)
MA (1) MA30867B1 (es)
MX (1) MX2009003882A (es)
NO (1) NO20091451L (es)
WO (1) WO2008048866A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
UY33766A (es) 2010-12-06 2012-06-29 Glaxo Group Ltd COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
WO2012080497A2 (en) 2010-12-17 2012-06-21 Glaxo Group Limited Methods of treatment and prevention of eye diseases
TW201321382A (zh) 2011-07-27 2013-06-01 Glaxo Group Ltd 化合物
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PE20151251A1 (es) 2013-01-25 2015-09-10 Glaxosmithkline Ip Dev Ltd Derivados [5,6] biciclicos de imidazo pirimidona con actividad sobre enzimas lp-pla2
WO2014114249A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
EP4056571A4 (en) 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437862T1 (de) 2000-02-16 2009-08-15 Smithkline Beecham Plc Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
AU2002361972A1 (en) * 2001-12-07 2003-06-17 Societe De Technologie Michelin Method for preparing butadiene/isoprene copolymers and resulting copolymers
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds

Also Published As

Publication number Publication date
CA2672926A1 (en) 2008-04-24
WO2008048866A2 (en) 2008-04-24
BRPI0719861A2 (pt) 2014-06-03
CO6180449A2 (es) 2010-07-19
CR10729A (es) 2009-05-25
NO20091451L (no) 2009-07-02
US7705005B2 (en) 2010-04-27
US20080090853A1 (en) 2008-04-17
EP2081915A4 (en) 2011-11-16
WO2008048866A3 (en) 2008-12-24
IL197960A0 (en) 2009-12-24
EA200970379A1 (ru) 2009-08-28
AU2007312995A1 (en) 2008-04-24
JP2010506851A (ja) 2010-03-04
KR20090079227A (ko) 2009-07-21
MA30867B1 (fr) 2009-11-02
EP2081915A2 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
MX2009003882A (es) Compuestos heteroaromaticos biciclicos.
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
MY153910A (en) BICYCLIC y-AMINO ACID DERIVATIVE
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2008114819A1 (ja) 新規アデニン化合物
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
MY177250A (en) Novel nicotinamide derivative or salt thereof
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
MY169179A (en) Novel piperidine compound or salt thereof
MY152972A (en) Azabicyclo compound and salt thereof
MX2009010024A (es) Nuevo compuesto de adenina.
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
MX2010007977A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2015007883A (es) Compuestos para protección de células.
MY183326A (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
PH12018502012B1 (en) Griseofulvin compound
MX2011009147A (es) Sales de adicion de trometamina con derivados de acido azabifenilaminobenzoico como inhibidores de dhodh.
NI200900181A (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos.
TW200612920A (en) Novel imidazolidine derivatives
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
PH12013501840A1 (en) Nitrogen-containing saturated heterocyclic compound
TW200716527A (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives

Legal Events

Date Code Title Description
HH Correction or change in general